

Table 1: Trial Patient Summary

Treatment	TNO	Gender	Time from Diag (Years)	Age (years)	Disease Type	Prev of Treatment (N)	Time on Treatment (days)	Discontinuation Reason	Rea- DLT	Mutation: ATM or SF3B1
Cohort 1 (200mg bd Capsule)	1	Male	4.57	74	CLL	1	112	Progression	No	Mutated
	2	Male	4.22	53	MCL	7	13	Toxicity	Yes	Unmutated
Cohort 2 (200mg bd Capsule)	3	Male	7.28	59	CLL	3	126	Progression	No	Mutated
	4	Male	11.39	71	CLL	5	64	Progression	No	Mutated
	5	Male	5.39	69	CLL	2	83	Progression	No	Mutated
Cohort 3 (400mg bd Capsule)	6	Male	9.43	75	CLL	4	71	Progression	No	Mutated
	7	Male	6.09	63	CLL	3	17	Withdrew Consent	Yes	Unmutated
Cohort 4 (100mg bd Tablet)	8	Male	6.64	56	CLL	7	40	Death	Yes	Unmutated
	9	Female	2.15	65	T-PLL	3	14	Withdrew Consent	Yes	Mutated
Cohort 5 (100mg bd Tablet)	10	Male	9.35	61	CLL	4	8	Toxicity	Yes	Mutated
	11	Male	5.63	74	MCL	3	76	Progression	No	Unmutated
	12	Male	2.3	77	MCL	1	103	No response - not strictly progression. BTKi available.	No	Unmutated
Cohort 5 (100mg bd Tablet)	13	Male	0.82	66	T-PLL	1	133	Progression	No	Mutated
	14	Male	10.25	72	MCL	6	35	Progression	No	Unmutated
	15	Female	13	77	CLL	6	83	Progression	No	Mutated